Prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Zhou, Yunlan ^a   Bian, Bingxian ^a   Yuan, Xiangliang ^a   Xie, Guohua ^a   Ma, Yanhui ^a   Shen, Lisong ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN;

ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CIRCULATING TUMOR CELL; DISEASE FREE SURVIVAL; HUMAN; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; SYSTEMATIC REVIEW; BLOOD; FEMALE; META ANALYSIS; OVARY TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR EMBOLISM;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASTIC CELLS, CIRCULATING; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84939201440     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130873     Document Type: Article

References (26)

1. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Database: GLOBOCAN [Internet]. Available: Http://globocan.iarc.fr.
2. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004; 3(4): 355-366. PMID: 14764655.
3. Sevinc A, Adli M, Kalender ME, Camci C. Benign causes of increased serum CA-125 concentration. Lancet Oncol. 2007; 8(12): 1054-1055. PMID: 18054877.
4. Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, et al. Meta-Analysis of the prognostic value of circulating tumor cells in breast cancer. Clinical Cancer Research. 2012; 18(20): 5701-5710. doi:10.1158/1078-0432.CCR-12-1587 PMID: 22908097.
5. Groot Koerkamp B, Rahbari NN, Büchler MW, Koch M, Weitz J. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: A meta-analysis. Ann Surg Oncol. 2013; 20(7): 2156-2165. doi:10.1245/s10434-013-2907-8 PMID: 23456317.
6. Wang S, Zheng G, Cheng B, Chen F, Wang Z, Chen Y, et al. Circulating tumor cells (CTCs) detected by RT-PCR and its prognostic role in gastric cancer: A meta-analysis of published literature. PLoS One. 2014; 9(6): E99259. doi:10.1371/journal.pone.0099259 PMID: 24901848.
7. Wang J, Wang K, Xu J, Huang J, Zhang T. Prognostic significance of circulating tumor cells in nonsmall- cell lung cancer patients: A meta-analysis. PLoS One. 2013; 8(11): E78070. doi:10.1371/journal.pone.0078070 PMID: 24223761.
8. Han L, Chen W, Zhao Q. Prognostic value of circulating tumor cells in patients with pancreatic cancer: A meta-analysis. Tumour Biol. 2014; 35(3): 2473-2480. doi:10.1007/s13277-013-1327-5 PMID: 24218336.
9. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8: 16. PMID: 17555582.
10. Whitehead A. Meta-analysis of controlled clinical trial. 1st ed. Chichester: John Wiley & Sons, Ltd; 2002.
11. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-Analysis. 1st ed. Chichester: John Wiley & Sons, Ltd; 2009.
12. McGauran N, Wieseler B, Kreis J, Schüler YB, Kölsch H, Kaiser T, et al. Reporting bias in medical research-a narrative review. Trials. 2010; 11: 37. doi:10.1186/1745-6215-11-37 PMID: 20388211.
13. Marth C, Kisic J, Kaern J, Tropé C, Fodstad Ø. Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis. Cancer. 2002; 94(3): 707-712. PMID: 11857303.
14. Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study. Gynecol Oncol. 2011; 123(1): 19-26. doi:10.1016/j.ygyno.2011.06.022 PMID: 21752435.
15. Judson PL, Geller MA, Bliss RL, Boente MP, Downs LS Jr, Argenta PA, et al. Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer. Gynecol Oncol. 2003, 91(2): 389-394. PMID: 14599871.
16. Liu JF, Kindelberger David, Doyle Courtney, Lowe A, Barry WT, Matulonis UA. Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol Oncol. 2013, 131(2): 352-356. doi:10.1016/j.ygyno.2013.08.006 PMID: 23954902.
17. Sang M, Wu X, Fan X, Sang M, Zhou X, Zhou N. Multiple MAGE-A genes as surveillance marker for the detection of circulating tumor cells in patients with ovarian cancer. Biomarkers. 2014; 19(1): 34-42. doi:10.3109/1354750X.2013.865275 PMID: 24320162.
18. Pearl ML, Zhao Q, Yang J, Dong H, Tulley S, Zhang Q, et al. Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer. Gynecol Oncol. 2014; 134(3): 581-590. doi:10.1016/j.ygyno.2014.06.013 PMID: 24972191.
19. Poveda A, Kaye SB, McCormack R, Wang S, Parekh T, Ricci D, et al. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol Oncol. 2011; 122(3): 567-572. doi:10.1016/j.ygyno.2011.05.028 PMID: 21664658.
20. Fan T, Zhao Q, Chen JJ, Chen WT, Pearl ML. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol. 2009; 112(1): 185-191. doi:10.1016/j.ygyno.2008.09.021 PMID: 18954898.
21. Aktas B, Kasimir-Bauer S, Heubner M, Kimmig R, Wimberger P. (2011) Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy. Int J Gynecol Cancer 21(5): 822-830. doi:10.1097/IGC.0b013e318216cb91 PMID: 21613958.
22. Obermayr E, Castillo-Tong DC, Pils D, Speiser P, Braicu I, Van Gorp T, et al. Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance-a study of the OVCAD consortium. Gynecol Oncol. 2013; 128(1): 15-21. doi:10.1016/j.ygyno.2012.09.021 PMID: 23017820.
23. Kuhlmann JD, Wimberger P, Bankfalvi A, Keller T, Schöler S, Aktas B, et al. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. Clin Chem. 2014; 60(10): 1282-1289. doi:10.1373/clinchem.2014.224808 PMID: 25015375.
24. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4): 704-715. doi:10.1016/j.cell.2008.03.027 PMID: 18485877.
25. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells:approaches to isolation and characterization. J Cell Biol. 2011; 192(3): 373-382. doi:10.1083/jcb.201010021 PMID: 21300848.
26. Wicha MS, Hayes DF. Circulating tumor cells: Not all detected cells are bad and not all bad cells are detected. J Clin Oncol. 2011; 29(12): 1508-1511. doi:10.1200/JCO.2010.34.0026 PMID: 21422428.